This method alone decreased tumor volume and increased CD8+ T cell production of IFNg and, together with anti-PD-1, elicited a more robust anti-tumor effect in murine mammary carcinoma tumors[96]. The gene discussed is PDCD1; the disease is breast carcinoma.